Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 4/20 | 0.85 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.85 |
| ▸ | ALPI | P09923 | 1/20 | 0.85 |
| ▸ | PKM | P14618 | 1/20 | 0.85 |
| ▸ | XIAP | P98170 | 1/20 | 0.85 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.61 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.61 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.61 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | LTA4H | P09960 | 1/20 | 0.53 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.53 |
| ▸ | KYNU | Q16719 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | LCK | P06239 | 1/20 | 0.51 |
| ▸ | FYN | P06241 | 1/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dl-Phenylalanine SCHEMBL29069525 | 1.00 | SLC7A5 (0.85) | SLC7A5PTGS1ALPIPKMXIAP | |
| Dl-Phenylalanine SCHEMBL1449124 | 0.92 | SLC7A5 (1.00) | SLC7A5PTGS1ALPIPKMXIAP | |
| Phenylalanine SCHEMBL16398197 | 0.92 | SLC7A5 (1.00) | SLC7A5PTGS1ALPIPKMXIAP | |
| Dl-Phenylalanine SCHEMBL15671104 | 0.92 | SLC7A5 (1.00) | SLC7A5PTGS1ALPIPKMXIAP | |
| Dl-Phenylalanine SCHEMBL385804 | 0.92 | SLC7A5 (1.00) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL23159186 | 0.92 | SLC7A5 (1.00) | SLC7A5PTGS1ALPIPKMXIAP | |
| Dl-Phenylalanine SCHEMBL8118 | 0.92 | SLC7A5 (1.00) | SLC7A5PTGS1ALPIPKMXIAP | |
| Dl-Phenylalanine SCHEMBL16398196 | 0.92 | SLC7A5 (1.00) | SLC7A5PTGS1ALPIPKMXIAP | |
| Phenylalanine SCHEMBL8119 | 0.92 | SLC7A5 (1.00) | SLC7A5PTGS1ALPIPKMXIAP | |
| D-Phenylalanine SCHEMBL837632 | 0.92 | SLC7A5 (1.00) | SLC7A5PTGS1ALPIPKMXIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024034685-A1 | AFFIBODY MICELLE DRUG CONJUGATE | 興和株式会社 | 2024-02-15 | — | — | WO | claimed |
| WO-2024034684-A1 | NEW DRUG COMPLEX | 興和株式会社 | 2024-02-15 | — | — | WO | claimed |
| US-20240009314-A1 | COMPOSITIONS AND METHODS FOR TARGETING TUMOR-ASSOCIATED MACROPHAGES | RESOLUTE SCIENCE (US) | 2024-01-11 | — | — | US | claimed |
| CN-116801871-A | Combination therapy | 思进公司 | 2023-09-22 | — | — | CN | claimed |
| EP-4240415-A1 | COMBINATION-THERAPY ANTIBODY DRUG CONJUGATE WITH IMMUNE CELL INHIBITOR | Seagen Inc. (US) | 2023-09-13 | — | — | EP | claimed |
| US-20230270877-A1 | Combination Therapy | SEAGEN INC. (US) | 2023-08-31 | — | — | US | claimed |
| EP-4199936-A1 | COMPOSITIONS AND METHODS FOR TARGETING TUMOR-ASSOCIATED MACROPHAGES | Resolute Science, Inc. (US) | 2023-06-28 | — | — | EP | claimed |
| WO-2022098972-A1 | COMBINATION-THERAPY ANTIBODY DRUG CONJUGATE WITH IMMUNE CELL INHIBITOR | SEAGEN INC. (US) | 2022-05-12 | — | — | WO | claimed |
| WO-2022040580-A1 | COMPOSITIONS AND METHODS FOR TARGETING TUMOR-ASSOCIATED MACROPHAGES | RESOLUTE SCIENCE (US) | 2022-02-24 | — | — | WO | claimed |
| EP-3903812-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | Agensys, Inc. (US) | 2021-11-03 | — | — | EP | claimed |
| US-9314538-B2 | Nucleic acid molecules encoding antibody drug conjugates (ADC) that bind to 191P4D12 proteins | AGENSYS, INC. (US) | 2016-04-19 | — | — | US | claimed |
| CN-110352074-B | Cysteine mutant antibodies for conjugation | 思进股份有限公司 | 2024-07-16 | — | — | CN | disclosed |
| US-20240207431-A1 | USE OF ANTIBODY-DRUG CONJUGATE IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITOR IN TREATMENT OF UROTHELIAL CANCER | REMEGEN CO LTD (CN) | 2024-06-27 | — | — | US | disclosed |
| US-20240207424-A1 | USE OF HER2-TARGETING ANTIBODY-DRUG CONJUGATE IN TREATMENT OF HER2-LOW EXPRESSING BREAST CANCER | REMEGEN CO LTD (CN) | 2024-06-27 | — | — | US | disclosed |
| US-20240182580-A1 | ANTI-CD74 ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI CD74 ANTIBODY CONJUGATES AND METHODS OF USING ANTI-CD74 ANTIBODY CONJUGATES | SUTRO BIOPHARMA INC (US) | 2024-06-06 | — | — | US | disclosed |
| EP-1594542-A4 | ANTI-CD70 ANTIBODY-DRUG CONJUGATES AND THEIR USE FOR THE TREATMENT OF CANCER AND IMMUNE DISORDERS | SEATTLE GENETICS INC (US) | 2007-05-02 | — | — | EP | disclosed |
| US-20060233794-A1 | Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders | SEATTLE GENETICS, INC. (US) | 2006-10-19 | — | — | US | disclosed |
| EP-1594542-A2 | ANTI-CD70 ANTIBODY-DRUG CONJUGATES AND THEIR USE FOR THE TREATMENT OF CANCER AND IMMUNE DISORDERS | Seattle Genetics, Inc. (US) | 2005-11-16 | — | — | EP | disclosed |
| WO-2004073656-A9 | ANTI-CD70 ANTIBODY-DRUG CONJUGATES AND THEIR USE FOR THE TREATMENT OF CANCER AND IMMUNE DISORDERS | SEATTLE GENETICS INC (US) | 2005-09-01 | — | — | WO | disclosed |
| WO-2004073656-A2 | ANTI-CD70 ANTIBODY-DRUG CONJUGATES AND THEIR USE FOR THE TREATMENT OF CANCER AND IMMUNE DISORDERS | SEATTLE GENETICS, INC. (US) | 2004-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240207431-A1 | USE OF ANTIBODY-DRUG CONJUGATE IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITOR IN TREATMENT OF UROTHELIAL CANCER | CD274, PDCD1LG2, PDCD1 | SLC7A5 2424/4885PTGS1 1926/4885ALPI 2221/4885 |
| US-20240207424-A1 | USE OF HER2-TARGETING ANTIBODY-DRUG CONJUGATE IN TREATMENT OF HER2-LOW EXPRESSING BREAST CANCER | ERBB2, FCGR2A, EGFR | SLC7A5 309/4885PTGS1 3436/4885ALPI 3655/4885 |
| US-20060233794-A1 | Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders | CD74, CD63, CD2 | SLC7A5 1977/4885PTGS1 4227/4885ALPI 1497/4885 |
| US-20230270877-A1 | Combination Therapy | FCGR3B, CD22, CD47 | SLC7A5 4300/4885PTGS1 4594/4885ALPI 3358/4885 |
| US-20240009314-A1 | COMPOSITIONS AND METHODS FOR TARGETING TUMOR-ASSOCIATED MACROPHAGES | CD47, CD68, CD14 | SLC7A5 1587/4885PTGS1 3043/4885ALPI 3721/4885 |
| US-20240182580-A1 | ANTI-CD74 ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI CD74 ANTIBODY CONJUGATES AND METHODS OF USING ANTI-CD74 ANTIBODY CONJUGATES | CD74, CD63, CD99 | SLC7A5 2691/4885PTGS1 4826/4885ALPI 1470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.